Sentences with phrase «of austerity programs»

For weaker economies in the euro zone that are seeing subdued domestic demand as a result of austerity programs, there were also encouraging signs in the trade figures for August.

The phenomenon is now recognized as an inherent stage of austerity programs.

But to the government's credit, it has hit most of its spending targets in the first few years of the austerity program Flaherty.

Not exact matches

The first group of so - called debt hawks sees another Great Recession coming and wants national governments to focus on austerity programs aimed at deficit reduction because rising sovereign debts are behind our current economic woes.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Even with austerity programs in place, the eurozone's collective budget deficit this year will exceed 4.5 % of GDP.

After more than two years of financial crisis, international bailouts, a huge debt writedown and Europe's harshest austerity program, Greek voters have been given a chance to hit back at the parties that got them into this mess.

The so - called austerity programs of bailout # 1 have not been fully implemented, and none of the austerity from bailout # 2 has been implemented.

The accompanying chart shows the incredible impact of the ongoing austerity programs in Europe.

But as cities, counties and states compete for economic development, spending on such programs nationwide has climbed into the billions of dollars, even in an era of fiscal austerity.

After a contentious period of negotiations, the odds of a so - called «Grexit,» or Greek exit from the euro, were drastically reduced as Greece begrudgingly accepted an austerity program and Germany gave the European Stability Mechanism the green light to negotiate a third bailout.

Growth in most of the eurozone has remained tepid and reliant on continued central bank stimulus, though the European Central Bank's (ECB's) bond - purchasing program has been hampered by a scarcity of eligible bonds, as issuance from member governments is restricted by their austerity - driven policies.

Many analysts have long flagged a similar pitfall for the ECB's purchasing program, namely a scarcity of eligible bonds, as issuance from member governments has been restricted by their austerity - driven policies.

The character of this suffering moves theological attention to the social systems that shape our lives — economic, political, cultural — as well as to public events themselves (the Holocaust, programs and policies of economic austerity, military intervention, terrorism, ethnic nationalist expression, struggles for survival and freedom).

Austerity programs similar to those imposed on third - world countries by the International Monetary Fund may soon be required of the United States.

It is largely accepted that these programs lead to systemic macroeconomic instability across the continent and that these policies drove countries of the global south into «debt crisis, austerity, decline and conflict» (Bond) and «acute material scarcity» (Mbembe).

A faction of the Republican Party is pushing austerity budgets, including cuts to social programs that are popular with the middle class, such as Social Security (government - funded retirement pension) and Medicare (government - funded retirement health insurance).

Prior to the legislature's proposal for increased taxes, Vanderhoef had presented an austerity budget that called for the immediate sale of Summit Park as well as massive cuts in many other programs.

A ComRes poll for today's Independent has shown that 72 % of the public would like to see a change in the government's flagship austerity program.

Obama intended the prospect of the fiscal cliff's dramatic mandatory cuts in social programs to extort progressive Congressional Democrats into agreeing to inflict severe austerity by voting in favor of what Obama hoped would be massive cuts in social programs and the safety net adopted by the Congressional «super committee» created by the same bipartisan austerity deal that created the «fiscal cliff.»

Stuckler and Basu argue that the harsh austerity measures and cutting of social programs adopted in response to the recent financial crisis have exacerbated public health problems and cost thousands of lives.

In response to the dawn of the financial crisis, in 2010 the Greek government along with Troika (European Union (EU), the International Monetary Fund (IMF) and the European Central Bank (ECB) introduced a strict austerity program in order to receive its first bailout loan.

Weingarten defended «the promise and potential of the Common Core standards,» while warning the program «may actually fail» due to testing backlash, accountability and austerity hawks, and implementation worse than Obamacare's.

Carr also explained that local school districts aggressively engage in competitive grant programs because in a time of austerity, it's imperative they find other revenue streams to support the needs of their traditional public schools.

While Chinese President Xi Jinping's austerity program and anti-corruption drive have hurt sales of everything from Rolex watches to first growth Bordeaux wines in Hong Kong, the top end of the art market is thriving.

While Van den Dorpel speaks through the specialized language of computer programming and perhaps abstrusely anthropomorphizes variably folk or «traditional» approaches to fine art, his work addresses more universal concerns related to ethics of economic austerity as well as those of inclusion, alienation, and social hierarchies.

Austerity - mongers claim that all public entities are «running out of money» for social programs and public spending projects, when the latter can at will create more currency units to pay for necessary projects.

«But as things get worse for Ontario's workers we've seen new levels of cooperation between injured workers, advocates, legal experts, labour unions, doctors and more, all coming together to fight against Ontario's austerity programs

«But as things get worse for Ontario's workers we've seen new levels of cooperation between injured workers, advocates, legal experts, labour unions, doctors and more, all coming together to fight against Ontario's austerity programs and fight for just compensation.»

Akin Gump Strauss Hauer & Feld, where RPL rose 12.9 percent, to $ 965,000, spent much of 2008 in an austerity program, eventually shedding 56 partners, a 16.9 percent reduction.

Just like we're seeing with social programs and public services across the map, a regime of extreme austerity reigns at the WSIB, and this has meant a

Just like we're seeing with social programs and public services across the map, a regime of extreme austerity reigns at the WSIB, and this has meant a full - fledged assault on people who have been injured or made ill at work.